主页 > 医学讨论 >
【drug-news】克利夫兰医疗中心心脏病专家Steven
Posted by Scott Hensley
The FDA advisory panel that just dissed Acomplia, Sanofi-Aventis’s weight-loss drug, dealt an indirect blow to a frequent and outspoken critic of the drug industry.
The thumbs-down for Acomplia marks at least the second time in a year that Cleveland Clinic cardiologist Steven Nissen “has been wrong about the promise of new drugs,” writes Ivan Oransky on the blog of The Scientist today.
Last October, Nissen (pictured, upper left) was part of a panel discussion that Oransky moderated at a meeting of health-care journalists in Cleveland. In preparation for the talk, Oransky asked the speakers to come with two ideas that the audience of reporters and editors might be interested in as potential stories. “Nissen brought two: Acomplia, which he said was a clever scientific idea and held real promise, and CETP inhibitors such as Pfizer’s torcetrapib,” he writes. “He was quite excited about both drugs, and was involved in trials of both at the time, which he disclosed.”
The panel discussion took place on Friday, Oct. 27. Three days later, Pfizer disclosed information that heightened concerns about torcetrapib’s tendency to raise blood pressure in patients taking it. Afterwards, Nissen acknowledged the findings raised the hurdle for approval of the medicine. But Pfizer halted development of torcetrapib in early December after excess deaths were found in a 15,000-patient study of the medicine.
The FDA advisors who voted down Acomplia yesterday dimmed the prospects for the drug being approved in the U.S. anytime soon.
Plenty of people besides Nissen were hopeful about both Acomplia and torcetrapib. And nobody can know for sure about the hypothesized benefits and risks of an experimental medicine until the clinical data are in. Still, Oransky concludes: “I think it’s worth noting the record of someone whose pronouncements on drugs are so often held up by drug industry critics and that make media headlines.” 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Cleveland Clinic Cardiologist’s Crystal Ball Imperfect
克利夫兰医疗中心心脏病专家预测失误
Posted by Scott Hensley
Scott Hensley供稿
The FDA advisory panel that just dissed Acomplia, Sanofi-Aventis’s weight-loss drug, dealt an indirect blow to a frequent and outspoken critic of the drug industry.
FDA顾问小组对赛诺菲一安万特公司的减肥药－利莫那班的否决，间接打击了医药工业中对此药频繁地公开评论。
The thumbs-down for Acomplia marks at least the second time in a year that Cleveland Clinic cardiologist Steven Nissen “has been wrong about the promise of new drugs,” writes Ivan Oransky on the blog of The Scientist today.
Ivan Oransky在他的博客“当代科学家”中写道：当利莫那班商标一年当中至少在第二次遭到反对时，克利夫兰医疗中心心脏病专家Steven Nissen“对于这种新药的认可已经成为错误”。
Last October, Nissen (pictured, upper left) was part of a panel discussion that Oransky moderated at a meeting of health-care journalists in Cleveland. In preparation for the talk, Oransky asked the speakers to come with two ideas that the audience of reporters and editors might be interested in as potential stories. “Nissen brought two: Acomplia, which he said was a clever scientific idea and held real promise, and CETP inhibitors such as Pfizer’s torcetrapib,” he writes. “He was quite excited about both drugs, and was involved in trials of both at the time, which he disclosed.”
去年10月，Nissen（照片，左上角）作为讨论小组的一员参加了Oransky主持的克利夫兰的医药卫生记者会议。为了准备此次讨论，Oransky要求发言者准备新闻报道人员感兴趣的有潜力的两个案例。Oransky 说：“Nissen准备的两个是：利莫那班，是一个科学智慧的方案并得到了真正的认可；胆固醇酯转移蛋白（CETP）抑制剂如：辉瑞的torcetrapib。他说他对这两种药物都很看好，正在进行它们的实验阶段。”
The panel discussion took place on Friday, Oct. 27. Three days later, Pfizer disclosed information that heightened concerns about torcetrapib’s tendency to raise blood pressure in patients taking it. Afterwards, Nissen acknowledged the findings raised the hurdle for approval of the medicine. But Pfizer halted development of torcetrapib in early December after excess deaths were found in a 15,000-patient study of the medicine.
讨论小组于10月27日，星期五开始讨论。三天后，辉瑞公司表示正在加强对患者服用torcetrapib后存在血压升高问题这一趋势的关注。随后，Nissen承认这一问题的发现使人们对此药的支持下降。由于15000个受试者中过多的死亡率，辉瑞公司于12月上旬停止了对torcetrapib的开发。
The FDA advisors who voted down Acomplia yesterday dimmed the prospects for the drug being approved in the U.S. anytime soon.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-14 05:11
医学,生命科学网